Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-07-10 am EDT			5-day change	1st Jan Change
282.00 ^DKK	-1.98%		-6.62%	-39.54%

Jul. 07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 23	U.S. Futures, European Stocks Down Slightly	DJ

DNB Carnegie trims Zealand Pharma price target to DKK 425 (440), reiterates Buy

Published on 06/10/2026 at 12:47 am EDT

Finwire - Translated by Marketscreener - See original

Add MarketScreener to your sources

ZEALAND PHARMA A/S

-1.98%

DNB Carnegie has lowered its price target for Zealand Pharma to DKK 425 from DKK 440, while maintaining a Buy rating on the stock.

Add MarketScreener to your sources

Latest news about Zealand Pharma A/S

Jul. 07	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 23	U.S. Futures, European Stocks Down Slightly	DJ
Jun. 18	Berenberg Lowers Zealand Pharma to Hold Amid 'Limited' Near-term Catalysts; Price Target Down	MT
Jun. 17	Auto1 Shifts into High Gear, BMW Downshifts
Jun. 17	U.S. Futures Edge Up, European Stocks Mixed	DJ
Jun. 17	Berenberg Downgrades Zealand Pharma to Hold from Buy, Sets Price Target at DKK300: BN	FW
Jun. 16	UBS Cuts Price Target on Zealand Pharma
Jun. 16	UBS Cuts Zealand Pharma PT, Affirms Buy Rating	MT
Jun. 16	UBS lowers price target for Zealand Pharma to DKK 540 (730), reiterates buy rating	FW
Jun. 12	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway
Jun. 12	After the Euphoria, a Traffic Jam on the Multi-Billion Dollar Highway
Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug	FW
Jun. 10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
Jun. 10	DNB Carnegie trims Zealand Pharma price target to DKK 425 (440), reiterates Buy	FW

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

544

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company